Imagion Biosystems Ltd. · ASX:IBX
Imagion Biosystems — Investor Presentation (July 2025)
12 slides from Imagion Biosystems's investor presentation, Aug 4, 2025
Slide 1: A Breakthrough for Cancer Detection
A Breakthrough for For personal use only Cancer Detection Molecular Magnetic Resonance Imaging Imagion Biosystems Limited ASX:IBX 1 IBX Investor Deck Copyright July 2025 | ImagionBiosystems.com
Slide 2: Forward Looking Statements
Forward Looking Statements This investor presentation (Presentation) has been prepared by Imagion Biosystems Limited (Imagion or the Company). This presentation does not constitute or form part of, and should not be construed as, an offer, solicitation or invitation to subscribe for, underwrite or o
Slide 3: Overview
Overview A clinical stage biotechnology company For personal use only developing a new class of molecular imaging technology for the early detection of cancer MagSense® Molecular Imaging Company Highlights Improves cancer detection compared to conventional imaging technologies by adding molecular sp
Slide 4: The Unmet Need
The Unmet Need For personal use only Screening Blood-based tests indicate risk but are non-diagnostic and require confirmation before treatment. Biopsy Provide certainty but are invasive, painful, error prone and Conventional Imaging provides anatomical challenging, often resulting in side effects o
Slide 5: Changing How We See Cancer
Clinical Pipeline Changing How We See Cancer MagSense® Imaging Agents For personal use only Specific Provides molecular confirmation of cancer, not just “suspicion”. MRI-based Detection Compatible across 50k+ MRI Safer scanners in use globally. MagSense® Imaging uses molecularly targeted imaging age
Slide 6: How MagSense molecular MRI works
Pre-Dose Post-Dose MagSense® nanoparticles enable molecular imaging by producing an How MagSense® molecular identifiable change in image contrast For personal use only MRI works when cancer cells are present MagSense particles are coated with unique Pre-Dose Post-Dose targeting moiety and administer
Slide 7: AI Enabling
Unique quantitative signature allows for Artificial Intelligence AI Enabling and Machine Learning algorithms for automated detection. For personal use only Existing iron-based AI diagnostics already show proof of concept. https://archive.ismrm.org/2021/3258.html 7 IBX Investor Deck Copyright July 20
Slide 8: Our Pipeline - $2B Markets
Our Pipeline - $2B Markets For personal use only Nodal Metastases in Primary Tumor Early Detection of HER2+ Breast Detection of Ovarian Cancer Cancer Prostate Cancer • 75% of cases diagnosed at late • 400,000 HER2+ Breast Cancer • 1M+ Prostate biopsies/year in stage diagnoses annually US • HER2+ tum
Slide 9: Large Markets with an Unmet Medical Need
Large Markets with an Unmet Medical Need • Global cancer incidence to rise 77% by 2050 with screening & diagnostic imaging costs growing at 6.7% CAGR • Molecular imaging to-date limited to methods using radioactivity Investment For personal use only due to MRI lacking specificity. Clear Path to Clin
Slide 10: Comparable Transactions
Comparable Transactions Strategic Partnering For personal use only Incumbents continue making attractive deals for differentiated clinical-stage assets Acquirer Target Value AUD Year Notes Strategic investment. Part of $70M $18M 2024 AUD financing transaction. $35M revenue at time of transaction. $3
Slide 11: Company & Leadership
Company & Leadership Robert Proulx MAICD Ward Detwiler Executive Chairman Chief Business Officer Robert has bee n CEO and Chairman of Imagion Ward is an experience d senior exe cutive in the For personal use only since 2015 bringing the technology and company medical imaging field. Most re cent ly,
Slide 12: For personal use only
For personal use only info@imagionbio.com | ASX:IBX 12 IBX Investor Deck Copyright July 2025 | ImagionBiosystems.com
Imagion Biosystems — Investor Presentation (July 2025) on 6ix